Categories Uncategorized

Brain Scientific Inc. (BRSF) is Making EEGs Accessible to 5,900 US Hospitals

  • 5,900 hospitals in the US lack the necessary extensive EEG tech
  • BRSF has created a cost-effective solution capable of supplying these hospitals with the equipment needed and broadening the reach of each neurologist
  • Emergency departments and hospitals are not the only markets in need of brain monitoring devices, and the industry is expected to grow to $208 billion by 2023

For most U.S. patients, an EEG is mostly unavailable during their journey, from home by EMS to the Emergency department. Additionally, for those patients who are admitted to the ICU, less than 45 percent of ICUs offer EEG monitoring. There are approximately 6,090 hospitals in the U.S., and around 5,900 of them lack the necessary extensive EEG tech coverage. There are several reasons for the lack of access:

  • Costs and/or space: 70% of US hospitals do not have the equipment for routine EEGs
  • Traditional EEGs require a specialized technician to administer and read the data
  • The equipment is bulky, which restricts accessibility and mobility
  • Twenty (20) states have less than 10 neurologists per 10,000 patients
  • Neurological care needs are increasing with the aging population

Brain Scientific (OTCQB: BRSF) has created a solution that makes EEG technology accessible. The Company’s neurotech ecosystem is making it possible for all hospitals to perform EEG tests efficiently. The technology is simple to use. Neurologists are given the resources necessary to automate the tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact.

BRSF’s ecosystem begins with the disposable and easy-to-apply clinical-grade NeuroCap(TM), patented and FDA-cleared, that comes in small, medium, large, and pediatric (extra small) sizes. This disposable headset comes equipped with 22 pre-gelled electrodes that eliminate the task of head measurement and electrode placement. This significantly reduces the amount of time needed to set up, limiting the amount of contact between the patient and the medical professional applying the headset. In addition, because it is disposable and does not need to be painstakingly cleaned before moving on to the next patient, more EEGs can be administered, and the risk of cross-infection is significantly reduced.

The NeuroEEG(TM), patented and FDA cleared, is a portable and wireless EEG amplifier that fits into the palm of your hand and is used to monitor electrical brain activity. 

By making EEG technology more available, BRSF has created a time-saving and cost-effective solution for hospitals while simultaneously meeting the growing need for additional neurological care of the communities those hospitals serve.

Emergency departments and hospitals are not the only markets that require brain monitoring devices. Improved technology is necessary in specialized niche markets that address Alzheimer’s disease, traumatic brain injury, depression, epilepsy, ADHD, stroke, sleep disorders, dementia, migraine, and more. It’s estimated that the U.S. medical device industry will grow to $208 billion by 2023, and BRSF is ready to meet that increasing need.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit…

21 hours ago

Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy

Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results,…

22 hours ago

Spanish Patient Highlights Risks of Poorly Cooked Pork

Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…

5 days ago

Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients

While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…

6 days ago

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…

7 days ago

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies 

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…

7 days ago